In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1
In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retinal fluid at week 16 and year one with Beovu1
In a key pre-specified secondary endpoint, over half of Beovu 6mg patients (56% in HAWK and 51% in HARRIER) were maintained on three-month dosing intervals immediately after the loading phase through year one1
Frequent injections are a common reason patients drop off treatment for wet AMD, a leading cause of blindness that affects more than 20M people worldwide2-4
Basel, December 13, 2019 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu® (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD).
“Today’s CHMP opinion brings us another step closer to providing wet AMD patients in Europe with a new treatment option,” said Nikos Tripodis, Worldwide Franchise Head, Novartis Ophthalmology. “At Novartis, we remain committed to reimagining treatments for patients suffering from wet AMD, a leading cause of blindness worldwide.”
Wet AMD is caused by uncontrolled VEGF, a protein that promotes abnormal blood vessel formation underneath the macula, the area of the retina responsible for sharp, central vision5,6. These blood vessels are fragile and leak fluid, disrupting the normal retinal architecture and ultimately causing damage to the macula5,6. By inhibiting VEGF, Beovu is designed to suppress the growth of abnormal blood vessels and the potential for fluid leakage into the retina1.
The positive CHMP opinion is based on findings from the Phase III, global, head-to-head HAWK and HARRIER clinical trials, in which Beovu demonstrated non-inferiority versus aflibercept in mean change in best-corrected visual acuity from baseline to year one1. In both trials, approximately 30% of patients treated with Beovu gained at least 15 letters at year one1.*
In pre-specified secondary endpoints, fewer patients treated with Beovu 6mg versus aflibercept had intra-retinal and/or sub-retinal fluid at week 16 (35% fewer patients in both HAWK and HARRIER) and at year one (30% fewer patients in HAWK and 41% fewer patients in HARRIER)1. Significant reductions in central subfield thickness were also seen with Beovu1.
Additionally, over half (56% in HAWK and 51% in HARRIER) of patients treated with Beovu 6mg maintained a three-month dosing interval immediately after the loading phase through year one1. Beovu patients who started on three-month dosing intervals after the loading phase had an 85% (HAWK) and 82% (HARRIER) probability of remaining on this interval through year one1.
Beovu exhibited an overall safety profile comparable to aflibercept. The most common adverse events (?5% of patients) with Beovu were vision blurred, cataract, conjunctival hemorrhage, vitreous floaters and eye pain1.
In October 2019, Novartis received the first, and so far the only, approval for Beovu from the U.S. Food and Drug Administration in the treatment of wet AMD. The European Commission will consider the CHMP opinion as it makes its final decision on the marketing authorization for Beovu. The decision is expected within three months.
*Patients receiving Beovu showed a numerical improvement in treatment versus aflibercept, but the p values did not result in statistical significance.
About Beovu (brolucizumab)
Beovu (brolucizumab, also known as RTH258) is the most clinically advanced humanized single-chain antibody fragment (scFv)1,7. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics7-9.
The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms8. Beovu is engineered to deliver the highest concentration of drug, providing more active binding agents than other anti-VEGFs1,7. In preclinical studies, Beovu inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction8-10. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema5. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions and suppress endothelial cell proliferation and vascular permeability5.
About the HAWK and HARRIER studies
With more than 1,800 patients across nearly 400 centers worldwide, HAWK (NCT02307682) and HARRIER (NCT02434328) are the first and only global head-to-head trials in patients with wet AMD that prospectively demonstrated efficacy at week 48 using an innovative q12w/q8w regimen, with a majority of patients on q12w immediately following the loading phase1. Both studies are 96-week prospective, randomized, double-masked multi-center studies and part of the Phase III clinical development of Beovu1. The studies were designed to compare the efficacy and safety of intravitreal injections of brolucizumab 6 mg (HAWK and HARRIER) and 3 mg (HAWK only) versus aflibercept 2 mg in patients with wet AMD1.
About wet age-related macular degeneration
Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America, Europe, Australia and Asia, impacting an estimated 20 million people worldwide3,4,11. Wet AMD occurs when abnormal blood vessels form underneath the macula, the area of the retina responsible for sharp, central vision6,12,13. These blood vessels are fragile and leak fluid, disrupting the normal retinal architecture and ultimately causing damage to the macula6,12,13.
Early symptoms of wet AMD include distorted vision (or metamorphopsia) and difficulties seeing objects clearly14. Prompt diagnosis and intervention are essential13. As the disease progresses, cell damage increases, further reducing vision quality6. This progression can lead to a complete loss of central vision, leaving the patient unable to read, drive or recognize familiar faces and potentially depriving them of their independence6,15. Without treatment, vision can rapidly deteriorate16.
About Novartis in ophthalmology
At Novartis, our mission is to discover new ways to improve and extend people's lives. In ophthalmology, we develop and deliver life-changing medicines and therapies for diseases and conditions from front to back of the eye, enabled by data and transformative technologies. Our ophthalmic solutions reach more than 150M people per year, from premature infants to the elderly.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that can generally be identified by words such as “positive CHMP opinion,” etc. etc..
For questions about the site or required registration, please contact email@example.com
Dugel P, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. https://www.ncbi.nlm.nih.gov/pubmed/30986442. Accessed December 2019.
Varano M, et al. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;9:2243–2250.
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and met analysis. Lancet Glob Health. 2014;2:106-16.
Singer M. Advances in the management of macular degeneration. F1000Prime Rep. 2014;6:29.
Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol. 2007;55(6):413-415.
National Eye Institute. Facts About Age-Related Macular Degeneration. Available at https://nei.nih.gov/eyedata/amd (link is external). Accessed December 2019.
Nimz EL, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates. The Association for Research in Vision and Ophthalmology (ARVO) annual meeting. 2016. Abstract 4996.
Escher D, et al. Single-chain antibody fragments in ophthalmology. Oral presentation at EURETINA congress. 2015. Abstract.
Gaudreault J, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. ARVO Annual Meeting abstract. Invest Ophthalmol Vis Sci 2012;53:3025. http://iovs.arvojournals.org/article.aspx?articleid=2354604 (link is external). Accessed December 2019.
Tietz J, et al. Affinity and Potency of RTH258 (ESBA1008), a Novel Inhibitor of Vascular Endothelial Growth Factor A for the Treatment of Retinal Disorders. IOVS. 2015; 56(7):1501.
Schmidt-Erfurth U, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144-1167.
World Health Organization. Priority eye diseases: Age-related macular degeneration. Available at http://www.who.int/blindness/causes/priority/en/index7.html (link is external). Accessed December 2019.
NHS Choices. Macular Degeneration. Available at http://www.nhs.uk/Conditions/Macular-degeneration/Pages/Introduction.aspx (link is external). Accessed December 2019.
Healthline. What is metamorphopsia? Available at https://www.healthline.com/health/metamorphopsia (link is external). Accessed December 2019.
Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97.
van Lookeren Campagne M, et al. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014; 232(2):151-64. doi: 10.1002/path.4266.
# # #